Cite

HARVARD Citation

    Ruzzolini, J. et al. (2017). Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH. Cancer letters. pp. 43-54. [Online]. 
  
Back to record